ID   MUSK_HUMAN              Reviewed;         869 AA.
AC   O15146; Q32MJ8; Q32MJ9; Q5VZW7; Q5VZW8;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   12-OCT-2022, entry version 188.
DE   RecName: Full=Muscle, skeletal receptor tyrosine-protein kinase;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:25029443};
DE   AltName: Full=Muscle-specific tyrosine-protein kinase receptor;
DE            Short=MuSK;
DE            Short=Muscle-specific kinase receptor;
DE   Flags: Precursor;
GN   Name=MUSK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING (ISOFORMS
RP   2 AND 3).
RX   PubMed=7546737; DOI=10.1016/0896-6273(95)90146-9;
RA   Valenzuela D.M., Stitt T.N., DiStefano P.S., Rojas E., Mattsson K.,
RA   Compton D.L., Nunez L., Park J.S., Stark J.L., Gies D.R., Thomas S.,
RA   LeBeau M.M., Fernald A.A., Copeland N.G., Jenkins N.A., Burden S.J.,
RA   Glass D.J., Yancopoulos G.D.;
RT   "Receptor tyrosine kinase specific for the skeletal muscle lineage:
RT   expression in embryonic muscle, at the neuromuscular junction, and after
RT   injury.";
RL   Neuron 15:573-584(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH DOK7.
RX   PubMed=20603078; DOI=10.1016/j.molcel.2010.06.007;
RA   Bergamin E., Hallock P.T., Burden S.J., Hubbard S.R.;
RT   "The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine
RT   kinase MuSK via dimerization.";
RL   Mol. Cell 39:100-109(2010).
RN   [5]
RP   NEDDYLATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-translational
RT   modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [6]
RP   CATALYTIC ACTIVITY, COFACTOR, PHOSPHORYLATION, AND MUTAGENESIS OF GLY-584;
RP   LYS-609 AND ASP-743.
RX   PubMed=25029443; DOI=10.1371/journal.pone.0102695;
RA   Bainbridge T.W., DeAlmeida V.I., Izrael-Tomasevic A., Chalouni C., Pan B.,
RA   Goldsmith J., Schoen A.P., Quinones G.A., Kelly R., Lill J.R., Sandoval W.,
RA   Costa M., Polakis P., Arnott D., Rubinfeld B., Ernst J.A.;
RT   "Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and
RT   ROR2 kinase domains.";
RL   PLoS ONE 9:E102695-E102695(2014).
RN   [7]
RP   VARIANT CMS9 MET-790, AND INVOLVEMENT IN CMS9.
RX   PubMed=15496425; DOI=10.1093/hmg/ddh333;
RA   Chevessier F., Faraut B., Ravel-Chapuis A., Richard P., Gaudon K.,
RA   Bauche S., Prioleau C., Herbst R., Goillot E., Ioos C., Azulay J.-P.,
RA   Attarian S., Leroy J.-P., Fournier E., Legay C., Schaeffer L., Koenig J.,
RA   Fardeau M., Eymard B., Pouget J., Hantai D.;
RT   "MUSK, a new target for mutations causing congenital myasthenic syndrome.";
RL   Hum. Mol. Genet. 13:3229-3240(2004).
RN   [8]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-27; MET-100; GLU-107; GLY-159; SER-222;
RP   ILE-413; PHE-629; ALA-644; SER-664; LEU-696; ASP-782; SER-819; LEU-829 AND
RP   HIS-858.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [9]
RP   VARIANT CMS9 ARG-344.
RX   PubMed=19949040; DOI=10.1212/wnl.0b013e3181c3fce9;
RA   Mihaylova V., Salih M.A., Mukhtar M.M., Abuzeid H.A., El-Sadig S.M.,
RA   von der Hagen M., Huebner A., Nurnberg G., Abicht A., Muller J.S.,
RA   Lochmuller H., Guergueltcheva V.;
RT   "Refinement of the clinical phenotype in musk-related congenital myasthenic
RT   syndromes.";
RL   Neurology 73:1926-1928(2009).
RN   [10]
RP   VARIANTS CMS9 ILE-605 AND VAL-727, AND CHARACTERIZATION OF VARIANTS CMS9
RP   ILE-605 AND VAL-727.
RX   PubMed=20371544; DOI=10.1093/hmg/ddq110;
RA   Maselli R.A., Arredondo J., Cagney O., Ng J.J., Anderson J.A., Williams C.,
RA   Gerke B.J., Soliven B., Wollmann R.L.;
RT   "Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7
RT   interaction.";
RL   Hum. Mol. Genet. 19:2370-2379(2010).
RN   [11]
RP   VARIANT CMS9 VAL-835, AND SUBCELLULAR LOCATION.
RX   PubMed=23326516; DOI=10.1371/journal.pone.0053826;
RA   Ben Ammar A., Soltanzadeh P., Bauche S., Richard P., Goillot E., Herbst R.,
RA   Gaudon K., Huze C., Schaeffer L., Yamanashi Y., Higuchi O., Taly A.,
RA   Koenig J., Leroy J.P., Hentati F., Najmabadi H., Kahrizi K., Ilkhani M.,
RA   Fardeau M., Eymard B., Hantai D.;
RT   "A mutation causes MuSK reduced sensitivity to agrin and congenital
RT   myasthenia.";
RL   PLoS ONE 8:E53826-E53826(2013).
RN   [12]
RP   VARIANT FADS1 THR-575, INVOLVEMENT IN FADS1, CHARACTERIZATION OF VARIANT
RP   FADS1 THR-575, AND FUNCTION.
RX   PubMed=25537362; DOI=10.1038/ejhg.2014.273;
RA   Tan-Sindhunata M.B., Mathijssen I.B., Smit M., Baas F., de Vries J.I.,
RA   van der Voorn J.P., Kluijt I., Hagen M.A., Blom E.W., Sistermans E.,
RA   Meijers-Heijboer H., Waisfisz Q., Weiss M.M., Groffen A.J.;
RT   "Identification of a Dutch founder mutation in MUSK causing fetal akinesia
RT   deformation sequence.";
RL   Eur. J. Hum. Genet. 23:1151-1157(2015).
RN   [13]
RP   VARIANT CMS9 GLU-38.
RX   PubMed=24183479; DOI=10.1016/j.nmd.2013.08.002;
RA   Gallenmuller C., Muller-Felber W., Dusl M., Stucka R., Guergueltcheva V.,
RA   Blaschek A., von der Hagen M., Huebner A., Muller J.S., Lochmuller H.,
RA   Abicht A.;
RT   "Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a
RT   novel missense mutation and heteroallelic deletion in MUSK.";
RL   Neuromuscul. Disord. 24:31-35(2014).
RN   [14]
RP   INVOLVEMENT IN FADS1.
RX   PubMed=25612909; DOI=10.1136/jmedgenet-2014-102730;
RA   Wilbe M., Ekvall S., Eurenius K., Ericson K., Casar-Borota O., Klar J.,
RA   Dahl N., Ameur A., Anneren G., Bondeson M.L.;
RT   "MuSK: a new target for lethal fetal akinesia deformation sequence
RT   (FADS).";
RL   J. Med. Genet. 52:195-202(2015).
CC   -!- FUNCTION: Receptor tyrosine kinase which plays a central role in the
CC       formation and the maintenance of the neuromuscular junction (NMJ), the
CC       synapse between the motor neuron and the skeletal muscle
CC       (PubMed:25537362). Recruitment of AGRIN by LRP4 to the MUSK signaling
CC       complex induces phosphorylation and activation of MUSK, the kinase of
CC       the complex. The activation of MUSK in myotubes regulates the formation
CC       of NMJs through the regulation of different processes including the
CC       specific expression of genes in subsynaptic nuclei, the reorganization
CC       of the actin cytoskeleton and the clustering of the acetylcholine
CC       receptors (AChR) in the postsynaptic membrane. May regulate AChR
CC       phosphorylation and clustering through activation of ABL1 and Src
CC       family kinases which in turn regulate MUSK. DVL1 and PAK1 that form a
CC       ternary complex with MUSK are also important for MUSK-dependent
CC       regulation of AChR clustering. May positively regulate Rho family
CC       GTPases through FNTA. Mediates the phosphorylation of FNTA which
CC       promotes prenylation, recruitment to membranes and activation of RAC1 a
CC       regulator of the actin cytoskeleton and of gene expression. Other
CC       effectors of the MUSK signaling include DNAJA3 which functions
CC       downstream of MUSK. May also play a role within the central nervous
CC       system by mediating cholinergic responses, synaptic plasticity and
CC       memory formation (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:25537362}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:25029443};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:25029443};
CC   -!- ACTIVITY REGULATION: Positively regulated by CK2. {ECO:0000250}.
CC   -!- SUBUNIT: Monomer (By similarity). Homodimer (Probable). Interacts with
CC       LRP4; the heterodimer forms an AGRIN receptor complex that binds AGRIN
CC       resulting in activation of MUSK (By similarity). Forms a heterotetramer
CC       composed of 2 DOK7 and 2 MUSK molecules which facilitates MUSK trans-
CC       autophosphorylation on tyrosine residue and activation. Interacts (via
CC       cytoplasmic part) with DOK7 (via IRS-type PTB domain); requires MUSK
CC       phosphorylation. Interacts with DVL1 (via DEP domain); the interaction
CC       is direct and mediates the formation of a DVL1, MUSK and PAK1 ternary
CC       complex involved in AChR clustering (By similarity). Interacts with
CC       PDZRN3; this interaction is enhanced by agrin (By similarity).
CC       Interacts with FNTA; the interaction is direct and mediates AGRIN-
CC       induced phosphorylation and activation of FNTA (By similarity).
CC       Interacts with CSNK2B; mediates regulation by CK2 (By similarity).
CC       Interacts (via the cytoplasmic domain) with DNAJA3 (By similarity).
CC       Interacts with NSF; may regulate MUSK endocytosis and activity (By
CC       similarity). Interacts with CAV3; may regulate MUSK signaling (By
CC       similarity). Interacts with RNF31 (By similarity).
CC       {ECO:0000250|UniProtKB:Q62838, ECO:0000305}.
CC   -!- INTERACTION:
CC       O15146; Q16543: CDC37; NbExp=3; IntAct=EBI-6423196, EBI-295634;
CC       O15146; P08238: HSP90AB1; NbExp=2; IntAct=EBI-6423196, EBI-352572;
CC   -!- SUBCELLULAR LOCATION: Postsynaptic cell membrane
CC       {ECO:0000269|PubMed:23326516}; Single-pass type I membrane protein
CC       {ECO:0000305}. Note=Colocalizes with acetylcholine receptors (AChR) to
CC       the postsynaptic cell membrane of the neuromuscular junction.
CC       {ECO:0000269|PubMed:23326516}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O15146-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15146-2; Sequence=VSP_035958, VSP_035959, VSP_035960;
CC       Name=3;
CC         IsoId=O15146-3; Sequence=VSP_035959, VSP_035960;
CC   -!- PTM: Ubiquitinated by PDZRN3. Ubiquitination promotes endocytosis and
CC       lysosomal degradation (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated (By similarity). Phosphorylation is induced by
CC       AGRIN in a LRP4-dependent manner (By similarity). Autophosphorylated
CC       (PubMed:25029443). Autophosphorylation at Tyr-554 is required for
CC       interaction with DOK7 which in turn stimulates the phosphorylation and
CC       the activation of MUSK (By similarity). {ECO:0000250|UniProtKB:Q61006,
CC       ECO:0000269|PubMed:25029443}.
CC   -!- PTM: Neddylated. {ECO:0000269|PubMed:20596523}.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 9, associated with
CC       acetylcholine receptor deficiency (CMS9) [MIM:616325]: A form of
CC       congenital myasthenic syndrome, a group of disorders characterized by
CC       failure of neuromuscular transmission, including pre-synaptic,
CC       synaptic, and post-synaptic disorders that are not of autoimmune
CC       origin. Clinical features are easy fatigability and muscle weakness
CC       affecting the axial and limb muscles (with hypotonia in early-onset
CC       forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and
CC       the facial and bulbar musculature (affecting sucking and swallowing,
CC       and leading to dysphonia). The symptoms fluctuate and worsen with
CC       physical effort. CMS9 is a disorder of postsynaptic neuromuscular
CC       transmission, due to deficiency of AChR at the endplate that results in
CC       low amplitude of the miniature endplate potential and current.
CC       {ECO:0000269|PubMed:15496425, ECO:0000269|PubMed:19949040,
CC       ECO:0000269|PubMed:20371544, ECO:0000269|PubMed:23326516,
CC       ECO:0000269|PubMed:24183479}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. MUSK mutations lead to
CC       decreased agrin-dependent AChR aggregation, a critical step in the
CC       formation of the neuromuscular junction.
CC   -!- DISEASE: Fetal akinesia deformation sequence 1 (FADS1) [MIM:208150]: A
CC       clinically and genetically heterogeneous group of disorders with
CC       congenital malformations related to impaired fetal movement. Clinical
CC       features include fetal akinesia, intrauterine growth retardation,
CC       polyhydramnios, arthrogryposis, pulmonary hypoplasia, craniofacial
CC       abnormalities, and cryptorchidism. FADS1 inheritance is autosomal
CC       recessive. {ECO:0000269|PubMed:25537362, ECO:0000269|PubMed:25612909}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=MuSK entry;
CC       URL="https://en.wikipedia.org/wiki/MuSK_protein";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF006464; AAB63044.1; -; mRNA.
DR   EMBL; AL157881; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL513328; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC109098; AAI09099.1; -; mRNA.
DR   EMBL; BC109099; AAI09100.1; -; mRNA.
DR   CCDS; CCDS48005.1; -. [O15146-1]
DR   CCDS; CCDS75874.1; -. [O15146-2]
DR   RefSeq; NP_001159752.1; NM_001166280.1. [O15146-2]
DR   RefSeq; NP_001159753.1; NM_001166281.1. [O15146-3]
DR   RefSeq; NP_005583.1; NM_005592.3. [O15146-1]
DR   AlphaFoldDB; O15146; -.
DR   SMR; O15146; -.
DR   BioGRID; 110679; 17.
DR   IntAct; O15146; 65.
DR   MINT; O15146; -.
DR   STRING; 9606.ENSP00000363571; -.
DR   BindingDB; O15146; -.
DR   ChEMBL; CHEMBL5684; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O15146; -.
DR   GuidetoPHARMACOLOGY; 1847; -.
DR   TCDB; 8.A.23.1.29; the basigin (basigin) family.
DR   GlyGen; O15146; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; O15146; -.
DR   PhosphoSitePlus; O15146; -.
DR   BioMuta; MUSK; -.
DR   jPOST; O15146; -.
DR   MassIVE; O15146; -.
DR   PaxDb; O15146; -.
DR   PeptideAtlas; O15146; -.
DR   PRIDE; O15146; -.
DR   Antibodypedia; 29502; 487 antibodies from 33 providers.
DR   DNASU; 4593; -.
DR   Ensembl; ENST00000189978.10; ENSP00000189978.6; ENSG00000030304.15. [O15146-2]
DR   Ensembl; ENST00000374448.9; ENSP00000363571.4; ENSG00000030304.15. [O15146-1]
DR   GeneID; 4593; -.
DR   KEGG; hsa:4593; -.
DR   MANE-Select; ENST00000374448.9; ENSP00000363571.4; NM_005592.4; NP_005583.1.
DR   UCSC; uc064vai.1; human. [O15146-1]
DR   CTD; 4593; -.
DR   DisGeNET; 4593; -.
DR   GeneCards; MUSK; -.
DR   GeneReviews; MUSK; -.
DR   HGNC; HGNC:7525; MUSK.
DR   HPA; ENSG00000030304; Tissue enhanced (brain, skeletal muscle).
DR   MalaCards; MUSK; -.
DR   MIM; 208150; phenotype.
DR   MIM; 601296; gene.
DR   MIM; 616325; phenotype.
DR   neXtProt; NX_O15146; -.
DR   OpenTargets; ENSG00000030304; -.
DR   Orphanet; 994; Fetal akinesia deformation sequence.
DR   Orphanet; 98913; Postsynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA31326; -.
DR   VEuPathDB; HostDB:ENSG00000030304; -.
DR   eggNOG; KOG1026; Eukaryota.
DR   GeneTree; ENSGT00940000158226; -.
DR   HOGENOM; CLU_000288_30_5_1; -.
DR   InParanoid; O15146; -.
DR   OMA; NERPWCY; -.
DR   OrthoDB; 471114at2759; -.
DR   PhylomeDB; O15146; -.
DR   TreeFam; TF106465; -.
DR   PathwayCommons; O15146; -.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   SignaLink; O15146; -.
DR   SIGNOR; O15146; -.
DR   BioGRID-ORCS; 4593; 8 hits in 1103 CRISPR screens.
DR   ChiTaRS; MUSK; human.
DR   GenomeRNAi; 4593; -.
DR   Pharos; O15146; Tchem.
DR   PRO; PR:O15146; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O15146; protein.
DR   Bgee; ENSG00000030304; Expressed in mucosa of stomach and 105 other tissues.
DR   ExpressionAtlas; O15146; baseline and differential.
DR   Genevisible; O15146; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0038062; F:protein tyrosine kinase collagen receptor activity; IBA:GO_Central.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007613; P:memory; ISS:UniProtKB.
DR   GO; GO:0007528; P:neuromuscular junction development; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:2000541; P:positive regulation of protein geranylgeranylation; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0008582; P:regulation of synaptic assembly at neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0071340; P:skeletal muscle acetylcholine-gated channel clustering; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF01392; Fz; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane;
KW   Congenital myasthenic syndrome; Developmental protein; Differentiation;
KW   Disease variant; Disulfide bond; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Magnesium; Membrane; Metal-binding; Muscle protein;
KW   Nucleotide-binding; Phosphoprotein; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Repeat; Signal; Synapse; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..869
FT                   /note="Muscle, skeletal receptor tyrosine-protein kinase"
FT                   /id="PRO_0000024446"
FT   TOPO_DOM        24..495
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        496..516
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        517..869
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          28..116
FT                   /note="Ig-like 1"
FT   DOMAIN          121..205
FT                   /note="Ig-like 2"
FT   DOMAIN          212..302
FT                   /note="Ig-like 3"
FT   DOMAIN          312..450
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DOMAIN          575..856
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        725
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         581..589
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         609
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         554
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q61006"
FT   MOD_RES         681
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q61006"
FT   MOD_RES         698
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q61006"
FT   MOD_RES         755
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q62838"
FT   CARBOHYD        222
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        338
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000250"
FT   DISULFID        49..99
FT                   /evidence="ECO:0000250"
FT   DISULFID        98..112
FT                   /evidence="ECO:0000250"
FT   DISULFID        142..190
FT                   /evidence="ECO:0000250"
FT   DISULFID        233..282
FT                   /evidence="ECO:0000250"
FT   DISULFID        317..382
FT                   /evidence="ECO:0000250"
FT   DISULFID        325..375
FT                   /evidence="ECO:0000250"
FT   DISULFID        366..406
FT                   /evidence="ECO:0000250"
FT   DISULFID        394..447
FT                   /evidence="ECO:0000250"
FT   DISULFID        398..434
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         209
FT                   /note="E -> EEESEPEQDTK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035958"
FT   VAR_SEQ         307..394
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035959"
FT   VAR_SEQ         454..462
FT                   /note="DYNKENLKT -> A (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035960"
FT   VARIANT         27
FT                   /note="A -> G (in dbSNP:rs56054734)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041748"
FT   VARIANT         38
FT                   /note="D -> E (in CMS9; dbSNP:rs775587809)"
FT                   /evidence="ECO:0000269|PubMed:24183479"
FT                   /id="VAR_072785"
FT   VARIANT         100
FT                   /note="T -> M (in dbSNP:rs35142681)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041749"
FT   VARIANT         107
FT                   /note="G -> E (in dbSNP:rs55786136)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041750"
FT   VARIANT         159
FT                   /note="S -> G (in dbSNP:rs35176182)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041751"
FT   VARIANT         222
FT                   /note="N -> S (in dbSNP:rs55826142)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041752"
FT   VARIANT         344
FT                   /note="P -> R (in CMS9; dbSNP:rs387906803)"
FT                   /evidence="ECO:0000269|PubMed:19949040"
FT                   /id="VAR_072786"
FT   VARIANT         413
FT                   /note="M -> I (in dbSNP:rs2274419)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_021930"
FT   VARIANT         575
FT                   /note="I -> T (in FADS1; reduces agrin-dependent AChR
FT                   aggregation and tyrosine kinase activity in developing
FT                   neuromuscular junction; dbSNP:rs751889864)"
FT                   /evidence="ECO:0000269|PubMed:25537362"
FT                   /id="VAR_072787"
FT   VARIANT         605
FT                   /note="M -> I (in CMS9; affects interaction with DOK7 and
FT                   impairs MUSK phosphorylation; altered AChR clustering;
FT                   dbSNP:rs766640370)"
FT                   /evidence="ECO:0000269|PubMed:20371544"
FT                   /id="VAR_066604"
FT   VARIANT         629
FT                   /note="L -> F (in dbSNP:rs34267283)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041753"
FT   VARIANT         644
FT                   /note="V -> A (in dbSNP:rs41279055)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041754"
FT   VARIANT         664
FT                   /note="N -> S (in dbSNP:rs55963442)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041755"
FT   VARIANT         696
FT                   /note="P -> L (in dbSNP:rs56126328)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041756"
FT   VARIANT         727
FT                   /note="A -> V (in CMS9; affects interaction with DOK7 and
FT                   impairs MUSK phosphorylation; altered AChR clustering;
FT                   dbSNP:rs397515450)"
FT                   /evidence="ECO:0000269|PubMed:20371544"
FT                   /id="VAR_066605"
FT   VARIANT         782
FT                   /note="E -> D (in dbSNP:rs34614566)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041757"
FT   VARIANT         790
FT                   /note="V -> M (in CMS9; does not affect catalytic kinase
FT                   activity; reduces protein expression and stability;
FT                   dbSNP:rs199476083)"
FT                   /evidence="ECO:0000269|PubMed:15496425"
FT                   /id="VAR_023046"
FT   VARIANT         819
FT                   /note="N -> S (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation; dbSNP:rs757577755)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041758"
FT   VARIANT         829
FT                   /note="V -> L (in dbSNP:rs578430)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_033837"
FT   VARIANT         835
FT                   /note="M -> V (in CMS9; reduces AChR aggregation in
FT                   developing neuromuscular junction)"
FT                   /evidence="ECO:0000269|PubMed:23326516"
FT                   /id="VAR_072788"
FT   VARIANT         858
FT                   /note="R -> H (in dbSNP:rs34115159)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041759"
FT   MUTAGEN         584
FT                   /note="G->C,D: Mild decrease in kinase activity."
FT                   /evidence="ECO:0000269|PubMed:25029443"
FT   MUTAGEN         609
FT                   /note="K->R: Severe loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:25029443"
FT   MUTAGEN         743
FT                   /note="D->N: Severe loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:25029443"
SQ   SEQUENCE   869 AA;  97056 MW;  3DDC20E179FA010C CRC64;
     MRELVNIPLV HILTLVAFSG TEKLPKAPVI TTPLETVDAL VEEVATFMCA VESYPQPEIS
     WTRNKILIKL FDTRYSIREN GQLLTILSVE DSDDGIYCCT ANNGVGGAVE SCGALQVKMK
     PKITRPPINV KIIEGLKAVL PCTTMGNPKP SVSWIKGDSP LRENSRIAVL ESGSLRIHNV
     QKEDAGQYRC VAKNSLGTAY SKVVKLEVEV FARILRAPES HNVTFGSFVT LHCTATGIPV
     PTITWIENGN AVSSGSIQES VKDRVIDSRL QLFITKPGLY TCIATNKHGE KFSTAKAAAT
     ISIAEWSKPQ KDNKGYCAQY RGEVCNAVLA KDALVFLNTS YADPEEAQEL LVHTAWNELK
     VVSPVCRPAA EALLCNHIFQ ECSPGVVPTP IPICREYCLA VKELFCAKEW LVMEEKTHRG
     LYRSEMHLLS VPECSKLPSM HWDPTACARL PHLDYNKENL KTFPPMTSSK PSVDIPNLPS
     SSSSSFSVSP TYSMTVIISI MSSFAIFVLL TITTLYCCRR RKQWKNKKRE SAAVTLTTLP
     SELLLDRLHP NPMYQRMPLL LNPKLLSLEY PRNNIEYVRD IGEGAFGRVF QARAPGLLPY
     EPFTMVAVKM LKEEASADMQ ADFQREAALM AEFDNPNIVK LLGVCAVGKP MCLLFEYMAY
     GDLNEFLRSM SPHTVCSLSH SDLSMRAQVS SPGPPPLSCA EQLCIARQVA AGMAYLSERK
     FVHRDLATRN CLVGENMVVK IADFGLSRNI YSADYYKANE NDAIPIRWMP PESIFYNRYT
     TESDVWAYGV VLWEIFSYGL QPYYGMAHEE VIYYVRDGNI LSCPENCPVE LYNLMRLCWS
     KLPADRPSFT SIHRILERMC ERAEGTVSV
//
